• 1. Distribution pattern and allocation of defects in hydrogenated ZnO thin films?
  Vitaly Gurylev,Chung-Yi Su,Tsong-Pyng Perng Phys. Chem. Chem. Phys., 2016,18, 16033-16038
• 2. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 3. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 4. Distribution and ecological risk assessment of typical antibiotics in the surface waters of seven major rivers, China?
  Environ. Sci.: Processes Impacts, 2021,23, 1088-1100
• 5. Enantiomorphic symmetry breaking in crystallization of molten sodium chlorate?
  Martin R. Ward,Gary W. Copeland,Andrew J. Alexander Chem. Commun., 2010,46, 7634-7636

Introduction to 6-Chloro-2-methylquinoline-3-carboxylic Acid Ethyl Ester (CAS No. 114858-39-8)

6-Chloro-2-methylquinoline-3-carboxylic Acid Ethyl Ester, identified by its CAS number 114858-39-8, is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the quinoline family, a class of molecules known for their broad spectrum of biological activities and utility in drug development. The structural features of 6-Chloro-2-methylquinoline-3-carboxylic Acid Ethyl Ester, particularly the presence of a chloro substituent at the 6-position and a methyl group at the 2-position, contribute to its unique chemical properties and potential pharmacological effects.

The quinoline scaffold is a privileged structure in medicinal chemistry, with numerous derivatives exhibiting antimicrobial, antimalarial, anti-inflammatory, and anticancer properties. The ethyl ester functionality at the 3-position of the quinoline ring enhances the solubility and bioavailability of the compound, making it a promising candidate for further investigation in drug discovery programs. The chloro group, on the other hand, can serve as a key pharmacophore, influencing both the electronic distribution and steric environment of the molecule, which are critical factors in determining its biological activity.

In recent years, there has been a surge in research focused on developing novel quinoline derivatives with enhanced therapeutic profiles. One notable area of interest is the exploration of quinolines as inhibitors of kinases and other enzymes involved in cancer progression. Studies have shown that certain quinoline derivatives can selectively target specific enzymatic pathways, leading to potent antitumor effects with reduced toxicity. 6-Chloro-2-methylquinoline-3-carboxylic Acid Ethyl Ester has been investigated for its potential as a kinase inhibitor, with preliminary studies suggesting that it can modulate the activity of enzymes such as tyrosine kinases, which are overexpressed in many cancer cell lines.

Another area where 6-Chloro-2-methylquinoline-3-carboxylic Acid Ethyl Ester shows promise is in the treatment of infectious diseases. Quinolines have a long history of use in combating parasitic infections, particularly malaria. The structural similarity between quinolines and certain natural products used by traditional medicine systems has inspired modern drug designers to explore new derivatives with improved efficacy and reduced side effects. The ethyl ester derivative of 6-Chloro-2-methylquinoline-3-carboxylic Acid may offer advantages over its parent compound by enhancing its ability to cross biological membranes, thereby improving its therapeutic index.

The synthesis of 6-Chloro-2-methylquinoline-3-carboxylic Acid Ethyl Ester involves multi-step organic reactions that require careful optimization to ensure high yield and purity. The process typically begins with the condensation of appropriately substituted acetic acid derivatives with ammonia or ammonium salts to form the quinoline core. Subsequent functionalization steps, such as chlorination and methylation, are performed to introduce the characteristic substituents at the 6- and 2-positions, respectively. The final step involves esterification to introduce the ethyl ester group at the 3-position.

Advances in synthetic methodologies have enabled researchers to produce complex heterocyclic compounds like 6-Chloro-2-methylquinoline-3-carboxylic Acid Ethyl Ester with greater efficiency and precision. Techniques such as flow chemistry and catalytic processes have reduced reaction times and improved yields, making it more feasible to conduct large-scale screenings for biological activity. Additionally, computational methods such as molecular modeling and virtual screening have accelerated the identification of promising lead compounds from vast chemical libraries.

The pharmacological evaluation of 6-Chloro-2-methylquinoline-3-carboxylic Acid Ethyl Ester has revealed several interesting properties that make it a valuable candidate for further development. In vitro studies have demonstrated its ability to inhibit the growth of various cancer cell lines by disrupting key signaling pathways involved in cell proliferation and survival. Furthermore, preclinical studies suggest that it may have immunomodulatory effects, making it potentially useful in treating autoimmune disorders.

One particularly intriguing aspect of 6-Chloro-2-methylquinoline-3-carboxylic Acid Ethyl Ester is its potential role as an anti-inflammatory agent. Chronic inflammation is implicated in numerous diseases, including cardiovascular disorders, neurodegenerative conditions, and metabolic syndromes. By modulating inflammatory pathways such as NF-kB and MAPK cascades, this compound may offer therapeutic benefits beyond its primary applications in oncology and infectious disease treatment.

The future direction of research on 6-Chloro-2-methylquinoline-3-carboxylic Acid Ethyl Ester will likely focus on optimizing its pharmacokinetic properties and exploring new therapeutic indications. Strategies such as prodrug design and combination therapy may enhance its efficacy while minimizing side effects. Collaborative efforts between academic researchers and pharmaceutical companies will be essential to translate preclinical findings into clinical applications that benefit patients worldwide.

In conclusion,6-Chloro-2-methylquinoline-3-carboxylic Acid Ethyl Ester (CAS No. 114858-39-8) represents a significant advancement in quinoline-based drug discovery. Its unique structural features combined with promising preclinical data position it as a versatile tool for developing novel therapeutics against cancer, infectious diseases, and inflammatory disorders. As research continues to uncover new applications for this compound,6-Chloro-2-methylquinoline-3-carboxylic Acid Ethyl Ester is poised to play an important role in shaping the future of medicinal chemistry.

• 15785-08-7(Ethyl 2-methylquinoline-3-carboxylate)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)